Millán-Pascual, Jorge http://orcid.org/0000-0003-2112-5964
Valero-López, Gabriel
Iniesta-Martinez, Francisca
Hellin-Gil, Maria Fuensanta
Jimenez-Veiga, Judith
López-Tovar, Isabel Alejandra
Morales-Ortiz, Ana
Meca-Lallana, José. E. http://orcid.org/0000-0001-5050-9890
Funding for this research was provided by:
Springer Healthcare Spain
Article History
Received: 16 June 2023
Accepted: 1 December 2023
First Online: 14 December 2023
Declarations
:
: Jorge Millán-Pascual and Gabriel Valero-López have received honoraria for lecturing or assistance for conference attendance from Biogen Idec, Janssen-Cilag, Merck Serono, Roche, and Sanofi Aventis; have received consulting or speaking fees from Biogen Idec, Merck Serono, and Roche; and have received funding for research projects or in the form of conference fees, mentoring, and assistance for conference attendance from Sanofi Aventis. José E. Meca-Lallana has received honoraria as a consultant, as a chairman or lecturer in meetings and has participated in clinical trials and other research projects promoted by Alexion, Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, and Sanofi.. Francisca Iniesta-Martinez, Maria Fuensanta Hellin-Gil, Judith Jimenez-Veiga, Isabel Alejandra López-Tovar and Ana Morales-Ortiz have nothing to disclose.
: The study protocol was approval by the Ethics Committee of the Virgen de la Arrixaca Clinical University Hospital (approval number: 2020-5-1–-5-HCUVA), and the study was conducted under the principles in the Declaration of Helsinki. Patients were informed about the study’s goals and written informed consent was obtained before enrolment, following Spanish law and Good Clinical Practices. We thank the participants of the study.